Citius Pharmaceuticals, Inc. Revenue from Contract with Customer, Including Assessed Tax
Citius Pharmaceuticals, Inc. (CTXR) reported Revenue from Contract with Customer, Including Assessed Tax of $90.00 thousand for the 12-month period ending 2022-09-30, per its 10-K filed 2022-12-22.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2022-12-22
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2022-09-30 was $0.00.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2021-09-30 was $0.00.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2020-09-30 was $0.00.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2019-09-30 was $0.00.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $90.00K, a 0.00% change from fiscal 2021.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $90.00K, a 0.00% change from fiscal 2020.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $90.00K, a 0.00% change from fiscal 2019.
- Citius Pharmaceuticals, Inc. revenue from contract with customer, including assessed tax for fiscal 2019 was $90.00K, a 20.00% increase from fiscal 2018.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 1 month | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $90.00K 10-K · filed 2022-12-22 | ||
| 2022-06-30 | $90.00K 10-Q · filed 2022-08-11 | |||
| 2021-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $90.00K 10-K · filed 2022-12-22 | ||
| 2021-06-30 | $90.00K 10-Q · filed 2022-05-12 | $90.00K 10-Q · filed 2022-08-11 | ||
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | $90.00K 10-K · filed 2021-12-15 | ||
| 2020-06-30 | $90.00K 10-Q · filed 2022-05-12 | $90.00K 10-Q · filed 2020-08-14 | ||
| 2019-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-16 | $90.00K 10-K · filed 2020-12-16 | ||
| 2019-06-30 | $90.00K 10-Q · filed 2020-05-14 | |||
| 2018-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-16 | $75.00K 10-K · filed 2019-12-16 | ||
| 2018-06-30 | $75.00K 10-Q · filed 2020-02-13 | |||
| 2017-09-30 | $50.00K 10-K · filed 2019-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |